Document is current

Article History

Received: 5 February 2026

Accepted: 16 March 2026

First Online: 16 April 2026

Declarations

:

: Jensen Yeung has served as a speaker, consultant, trialist, or received honoraria from AbbVie, Amgen, Apogee, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Galderma, Incyte, JAMP, Johnson & Johnson, Leo Pharma, Lilly, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. Jensen Yeung is an Editorial Board Member of Dermatology and Therapy , and was not involved in in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Parbeer Grewal has consulted, spoken for, or received grant funding and/or honoraria from AbbVie, Amgen, Anacor, Arcutis, Arena Pharmaceuticals, Avillion, Bausch Health/Valeant, Boehringer Ingelheim, BMS, Celgene, Cipher, Dermavant, Dermira, Eli Lilly, Galderma, GSK, Incyte, Innovaderm, Johnson & Johnson/Janssen, Leo Pharma, Med Plan, Meiji Seika Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharmaceuticals, Takeda, UCB, Vitae. Perla Lansang has consulted, spoken for, or received honoraria from AbbVie, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Regeneron, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharma, and UCB. Ron Vender has consulted, spoken for, or received grant funding and/or honoraria from AbbVie, Actelion, Amgen, Arcutis, Bausch-Health, Boehringer Ingelheim, BMS, Celgene, Centocor, Cipher, Demira, Dermavant, Eli Lilly, Galderma, GSK, Innovaderm, Janssen, Kabi-Care, Leo, Meiji, Merck, Novartis, Palladin, Pfizer, Regeneron, Sandoz, Sun Pharma, Takeda, UCB, and Viatris-Mylan. Marni Wiseman has served as consultant, speaker, advisory board member, and clinical trial investigator for AbbVie, Amgen, Arcutis, Asana BioSciences, AstraZeneca, Bausch Health, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly, Galderma, Glenmark, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Principia, PRCL Research, Regeneron, Sanofi, UCB, and La Roche-Posay. Rami Abou Zeinab and Maxime Barakat are employees at Bausch Health, Canada Inc. Vimal H Prajapati has been an advisor, consultant, and/or speaker for: AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipher, CorEvitas, Galderma, GlaxoSmithKline, Homeocan, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, Kenvue, Knight Therapeutics, LEO Pharma, Lilly, Medexus, Nia Health, Novartis, Organon, Paladin, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, and UCB; investigator for: AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Galderma, Incyte, J&J Innovative Medicine, Janssen, LEO Pharma, Lilly, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, Q32 Bio, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; received grants from: AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme.

: The protocol for the Can Target Psoriasis study (Pro00063845) was reviewed and approved by the Advarra® institutional review board on May 31, 2022, and adhered to the principles of the Declaration of Helsinki of 1964 and its later amendments, Good Clinical Practice guidelines, and relevant laws and regulations. Advarra®, established in 1983, offers institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance consulting services in North America. A Waiver of Informed Consent was granted on the grounds that (1) the study involves the secondary use of existing information, (2) no identifiable information was included, and (3) no individual data was transmitted or stored outside of Canada.